<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2016</study_start_year><data_sharing_plan>IPD Sharing (as of May 2023): No</data_sharing_plan><condition>Peritoneal Neoplasms</condition><condition>Carcinoma</condition><condition>Colorectal Cancer</condition><disease>Peritoneal Neoplasms</disease><disease>Carcinoma</disease><disease>Colorectal Cancer</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2252055</full_dataset_link><location>France</location><study_start_month>5</study_start_month><keyword>Oxaliplatin</keyword><keyword>Oxycodone</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC</name><description>This study determine the maximal tolerate dose</description><dates><creation>2016-05-15</creation></dates><accession>2252055</accession><cross_references><ClinicalTrials___gov>NCT03253133</ClinicalTrials___gov></cross_references></HashMap>